Genetic influence on pain and analgesic (oxycodone) requirement after breast cancer surgery.
Phase 1
- Conditions
- Women who are scheduled for breast cancer surgery.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- EUCTR2013-002774-51-FI
- Lead Sponsor
- Helsinki University Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Women, aged 18-75 years, who have breast cancer and who are scheduled to have breast resection or mastectomy with or without axillary clearance and who sign an informed consent form.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Patients who have known metastases (other than axillary lymph nodes), who have clinically relevant kidney or liver failure or who are allergic to oxycodone.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method